Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Zhang, Yu ^a   Johansson, Elisabet ^b   Miller, Marian L ^b   Jänicke, Reiner U ^c   Ferguson, Donald J ^d   Plas, David ^b   Meller, Jarek ^a   Anderson, Marshall W ^e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d MIAMI UNIVERSITY   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CHROMOSOME PROTEIN; ETOPOSIDE; PROTEIN BID; PROTEIN C9ORF82; STAUROSPORINE; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME DEFICIENCY; ENZYME INACTIVATION; FEEDBACK SYSTEM; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; MITOCHONDRION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; STRUCTURAL HOMOLOGY; DRUG EFFECT; GENETICS; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; ETOPOSIDE; HUMANS; MITOCHONDRIA; PROTEINS; RNA, SMALL INTERFERING; STAUROSPORINE;

EID: 80053607442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025284     Document Type: Article

References (37)

1. Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, et al. (1977) Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res 57: 1-6.
2. Park HH, Lo YC, Lin SC, Wang L, Yang JK, et al. (2007) The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu Rev Immunol 25: 561-86.
3. Fishcer U, Jänicke RU, Schulze-Osthoff K, (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10: 76-100.
4. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, et al. (2004) Taxol induces caspase-10-dependent apoptosis. J Bio Chem 279: 51057-67.
5. Thornberry NA, Lazebnik Y, (1998) Caspases: enemies within. Science 281: 1312-16.
6. Salvesen GS, Dixit VM, (1997) Caspases: intracellular signaling by proteolysis. Cell 91: 443.
7. Green D, Kroemer G, (1998) The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 8: 267-71.
8. Yang X, Chang HY, Baltimore D, (1998) Autoproteolytic activation of pro-caspases by oligomerization. Mol Cell 1: 319-25.
9. Mikhailov V, Mikhailova M, Degenhardt K, Venkatachalam MA, White E, et al. (2003) Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J Biol Chem 278: 536.
10. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, et al. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-92.
11. Hill JM, Morisawa G, Kim T, Huang T, Wei Y, et al. (2004) Identification of an expanded binding surface on the FADD death domain responsible for interaction with CD95/Fas. J Biol Chem 279: 1474-81.
12. Peter ME, Krammer PH, (2003) The CD95 (APO-1/Fas) DISC and beyond. Cell Death and Differ 10: 26-35.
13. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, et al. (2000) Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 19: 4563-73.
14. Filomenko R, Prévotat L, Rébé C, Cortier M, Jeannin JF, et al. (2006) Caspase 10 involvement in cycotoxic drug-induced apoptosis of tumor cells. Oncogene 25: 7635-45.
15. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, et al. (2001) Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97: 1378-87.
16. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B, et al. (2003) Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 22: 2236-47.
17. Li H, Zhu H, Xu C, Yuan J, (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501.
18. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X, (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-90.
19. Green DR, (2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4.
20. Cain K, Brown DG, Langlais C, Cohen GM, (1999) Caspase activation involves the formation of the aposome, a large (~700 kDa) caspase-activating complex. J Biol Chem 274: 22686-92.
21. Cowling V, Downward J, (2002) Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death and Differentiation 9: 1046-56.
22. Sharp DA, Lawrence DA, Ashkenzi A, (2005) Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280: 19401-9.
23. Shiio Y, Yamamoto T, Yamaguchi N, (1992) Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci USA 89: 5206-10.
24. Jaroszewski L, Rychlewski L, Li Z, Li W, Godzik A, (2005) FFAS03: a server for profile-profile sequence alignments. Nucleic Acids Res 33: W284-8.
25. Finn RD, Mistry J, Schuster-Bockler B, Griffiths-Jones S, Hollich V, et al. (2006) Pfam: clans, web tools and services. Nucleic Acids Res 34: D247-51.
26. Jänicke RU, Ng P, Sprengart ML, Porter AG, (1998) Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273: 15540-5.
27. Engels IH, Totzke G, Fischer U, Schulze-Osthoff K, Jänicke RU, (2005) Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol 25: 2808-18.
28. Fischer U, Stroh C, Schulze-Osthoff K, (2006) Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene 25: 152-9.
29. Manns J, Daubrawa M, Driessen S, Paasch F, Hoffmann N, et al. (2011) Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absences of Apaf-1. The FASEB Journal fj: 10-177527.
30. Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, et al. (2010) A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol 65: 383-389.
31. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, et al. (2008) Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 61 (3): 423-33.
32. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, et al. (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107 (6): 2517-24.
33. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, et al. (2006) Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of Oncology 17 (2): 334-40.
34. Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, et al. (2005) Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Journal of Clinical Oncology 23 (9): 1875-84.
35. Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, et al. (2004) Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Annals of Oncology 15 (2): 316-23.
36. Lee HJ, Pyo JO, Oh Y, Kim HJ, Hong SH, et al. (2007) YK.AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nature Cell Biol 11: 1303-10.
37. Rikhof B, Corn PG, El-Deiry WS, (2003) Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Canc Bio Therapy 2: 707-12.